Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Cellectar reports updates on Phase 1 study of iopoffosine I 131 in pHGG

Cellectar Biosciences (NASDAQ: CLRB) announced initial results as of June 10, 2025, from its CLOVER-2 Phase 1 trial evaluating iopoffosine I 131 in relapsed/refractory pediatric high-grade glioma (pHGG) patients...

June 11, 2025

Developments

Adial’s lead AUD candidate advances toward Phase 3 trial

Adial Pharmaceuticals (NASDAQ: ADIL) announced that its lead investigational candidate—AD04—a therapeutic agent for alcohol use disorder (AUD) is progressing toward a Phase 3 trial. According to Adial, as part of its...

June 11, 2025

Developments

First BPH patient treated using Profound’s TULSA-PRO with TULSA-AI Volume Reduction

Profound Medical (NASDAQ: PROF; TSX: PRN) announced that the first commercial benign prostatic hyperplasia (BPH) treatment utilizing the TULSA-PRO system’s new TULSA-AI Volume Reduction Module was successfully conducted...

June 10, 2025

Developments

Citius and Cardinal sign distribution agreement

Citius Oncology (NASDAQ: CTOR) announced it has entered into a distribution services agreement with Cardinal Health (NYSE: CAH). According to Citius, the agreement is designed to help provide access to LYMPHIR, an...

June 9, 2025

Developments

Leef acquires New York License

Leef Brands (CSE: LEEF; OTCQB: LEEEF) announced it has officially closed on the acquisition of a Type 1 Cannabis Processor License in New York, enabling the company to engage in extraction, blending, infusion...

June 9, 2025

Developments

Aytu signs agreement to commercialize Exxua for MDD

Aytu BioPharma (ASDAQ: AYTU) announced that it has signed an exclusive agreement with closely held Fabre-Kramer Pharmaceuticals to commercialize Exxua—extended-release antidepressant tablets—in the U.S. market for major...

June 9, 2025

Developments

Vaccines publishes key benefits of PharmaJet Tropis ID vaccine over IM SoC

Closely held PharmaJet announced that the results of an implementation research study—titled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An...

June 5, 2025

Developments

Perimeter launches OCT-Tissue Registry to power AI and imaging innovation

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced the launch of its optical coherence tomography (OCT)-Tissue Surveillance Registry—a database designed to collect thousands of images from surgical...

June 4, 2025

Developments

Leonard Wheeler, former NFL player, named global ambassador for Profound’s TULSA-PRO

Profound Medical (NASDAQ: PROF; TSX: PRN) today announced that it has entered into a consulting agreement with Leonard Wheeler—former NFL player, entrepreneur, author, corporate consultant, co-executive director of the...

June 4, 2025

Developments

Defence opens first U.S. laboratory

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) announced that it has opened its first U.S.-based laboratory in the Boston-Cambridge area. According to Defence, the new laboratory will allow the company to...

June 2, 2025

Developments

atai and Beckley to combine establishing market leader in psychedelic mental health therapies

atai Life Sciences (NASDAQ: ATAI) and closely held Beckley Psytech announced a definitive agreement to combine in an all-share transaction subject to Phase 2b success criteria of BPl-003 in patients with treatment...

June 2, 2025

Developments

Genflow and CER agree to long-term R&D collaboration

Genflow Biosciences (LSE:GENF; OTCQB:GENFF) has announced the signing of a master service agreement (MSA) with closely held CER Groupe—a long-standing partner—to strengthen long-term research and development (R&D)...

May 28, 2025

Developments

NeoGenomics introduces PanTracer genomic profiling tests at ASCO 2025

NeoGenomics (NASDAQ: NEO) has announced that it will debut its PanTracer Family genomic profiling tests for advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) in Chicago May 30—June 3, 2025...

May 28, 2025

Developments

Perimeter partners with Intermountain Health to study benefits of using OCT and AI to reduce cancer reoperations

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that it has entered into a development support agreement with Intermountain Health, creating the framework for the two organizations to partner on a...

May 23, 2025

Developments

FDA clears Quoin’s second QRX003 NS pivotal study

Quoin Pharmaceuticals (NASDAQ: QNRX) announced that the FDA has provided clearance to initiate a second Netherton Syndrome (NS) clinical pivotal study—CL-QRX003-002, for Quoin’s lead product QRX003. According to Quoin...

May 22, 2025

Developments

NorthStrive completes Phase 1 review for oral myostatin-engineered probiotic

NorthStrive Biosciences (NASDAQ:ELAB) announced the completion of a Phase I strategic research and literature synthesis for EL-22 (formerly BLS-M22), its first-in-class oral myostatin-engineered probiotic targeting...

May 22, 2025

Developments

Zura Bio launches global Phase 2 study of tibulizumab in HS

Zura Bio (NASDAQ:ZURA) announced that it has launched a global Phase 2 study—TibuSHIELD—to evaluate tibulizumab in 180 adults with moderate to severe hidradenitis suppurativa (HS) across Canada, the U.S. and Europe...

May 21, 2025

Developments

Neurogene announces treatment intended to reverse HLH associated with high-dose AAV

Neurogene (NASDAQ:NGNE) has announced an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) annual meeting this week describing a monitoring and treatment algorithm intended to reverse the rare...

May 16, 2025

Developments

CAMP4 presents translational data from SYNGAP1-related disorders program at ASGCT annual meeting

CAMP4 Therapeutics (NASDAQ:CAMP) has announced that three oral presentations on its SYNGAP1-related disorders and Urea Cycle Disorders (UCDs) programs, and shared favorable safety and pharmacokinetics data from the...

May 16, 2025

Developments

Ekso Bionics accepted into NVIDIA Connect program

Ekso Bionics Holdings (NASDAQ:EKSO) has announced its acceptance into the NVIDIA Connect program, enabling access to valuable tools and resources to support a new strategic initiative to build a proprietary foundation...

May 15, 2025

Developments

Social Capital’s Chamath Palihapitiya highlights latest developments on Perimeter Medical’s Next-gen, AI-driven B-Series OCT device on X

In a May 13, 2025 post on X, Chamath Palihapitiya, renowned Silicon Valley venture capitalist, entrepreneur, and former Facebook executive, provided the latest updates on Perimeter Medical Imaging AI (TSXV:PINK;...

May 14, 2025

Developments

Radiology Today spotlights Perimeter’s next-gen, AI-enabled B-Series OCT for interoperative cancer margin assessment during breast-conserving surgeries

The May issue of Radiology Today magazine features an interview with Andrew Berkeley, co-founder and chief innovation officer of Perimeter Medical Imaging AI (TSXV:PINK; OTCQX:PYNKF), and highlights both the...

May 13, 2025

Subscribe